Deciphera Pharmaceuticals, Inc (DCPH)

Etorro trading 970x250
Deciphera Pharmaceuticals, Inc (DCPH) Logo

About Deciphera Pharmaceuticals, Inc

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Address: 200 Smith Street, Waltham, MA, United States, 02451

Deciphera Pharmaceuticals, Inc News and around…

Latest news about Deciphera Pharmaceuticals, Inc (DCPH) common stock and company :

First Week of DCPH July 15th Options Trading
13 Jan, 2022 FinancialContent

Investors in Deciphera Pharmaceuticals Inc (DCPH) saw new options become available this week, for the July 15th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 183 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
10 Jan, 2022 FinancialContent

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Healthcare Conference. The Company will webcast its presentation today at 9:00 AM ET at https://investors.deciphera.com/events-presentations.

Analysts See 25% Gains Ahead For FYC
07 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $90.04 per unit.

Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 Jan, 2022 FinancialContent

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET.

Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...
24 Dec, 2021 Yahoo! Finance

New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
21 Dec, 2021 FinancialContent

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for QINLOCK® (ripretinib) in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib1.

Here is What Hedge Funds Think About Deciphera Pharmaceuticals, Inc. (DCPH)
10 Dec, 2021 Yahoo! Finance

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Deciphera: Why There Won’t Be a Quick Recovery
09 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traders might look at DCPH stock for a quick bounce after its 75% decline. But here's why that's not a great idea. The post Deciphera: Why There Won’t Be a Quick Recovery appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ...
09 Dec, 2021 Yahoo! Finance

Investment company Tekla Life Sciences Investors (Current Portfolio) buys Amgen Inc, Alkermes PLC, Novavax Inc, Intra-Cellular Therapies Inc, AstraZeneca PLC, sells Moderna Inc, Allakos Inc, Blueprint Medicines Corp, Ascendis Pharma A/S, BridgeBio Pharma Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Life Sciences Investors.

Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ...
09 Dec, 2021 Yahoo! Finance

Investment company Tekla Healthcare Investors (Current Portfolio) buys Amgen Inc, Guardant Health Inc, Icon PLC, IDEXX Laboratories Inc, Alnylam Pharmaceuticals Inc, sells Abbott Laboratories, Deciphera Pharmaceuticals Inc, BridgeBio Pharma Inc, Ascendis Pharma A/S, ResMed Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Healthcare Investors.

Analysts Forecast 25% Upside For The Holdings of FYC
06 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Growth AlphaDEX Fund ETF (FYC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $89.76 per unit.

691 Stocks Are Down Over 50% This Year
05 Dec, 2021 FinancialContent

It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date.

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
03 Dec, 2021 Yahoo! Finance

The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?
02 Dec, 2021 Yahoo! Finance

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
02 Dec, 2021 Yahoo! Finance

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
01 Dec, 2021 Yahoo! Finance

Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.

Deciphera Pharmaceuticals lays off more than a third of its staff
01 Dec, 2021 Yahoo! Finance

The Waltham drugmaker is laying off 140 people — 35% of its workforce — eliminating one of its drug programs and scaling back the European commercialization of another drug.

Why Deciphera Pharmaceuticals Shot 12% Higher Today
30 Nov, 2021 FinancialContent

The company announced a comprehensive restructuring program.

Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
30 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials. The post Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
30 Nov, 2021 FinancialContent

Deciphera Pharmaceuticals Inc(NASDAQ: DCPH) will undergo acorporate restructuring to eliminate 35% of its workforceand ...

Don’t Bet on a Deciphera Stock Comeback
30 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect DCPH stock to remain a clear-cut "avoid" situation. The post Don’t Bet on a Deciphera Stock Comeback appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
30 Nov, 2021 FinancialContent

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company’s cash runway.

Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
29 Nov, 2021 Yahoo! Finance

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

The Petri Dish: $2.5M for another Bob Langer startup, Decibel extends Regeneron deal
24 Nov, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.

Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
23 Nov, 2021 Yahoo! Finance

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

Deciphera's Qinlock Approved In Europe For Gastric Cancer
22 Nov, 2021 FinancialContent

TheEuropean Commission has approvedDeciphera Pharmaceuticals Inc's(NASDAQ: DCPH) Qinlock (ripretinib)for adult ...

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
22 Nov, 2021 FinancialContent

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the European Commission (EC) has approved QINLOCK® (ripretinib) in the European Union (EU) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib1. The EC decision is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. In September 2021, QINLOCK was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST2.

Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
16 Nov, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. The post Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

What 6 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
08 Nov, 2021 FinancialContent

Analysts have provided the following ratings for Deciphera Pharmaceuticals (NASDAQ:DCPH) within the last quarter: ...

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
08 Nov, 2021 FinancialContent

Upgrades For Nektar Therapeutics (NASDAQ:NKTR), Benchmark upgraded the previous rating of Hold to Buy. Nektar ...

Deciphera Pharmaceuticals, Inc (DCPH) is a NASDAQ Common Stock listed in , ,

970x250